<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876198</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2015_41</org_study_id>
    <nct_id>NCT02876198</nct_id>
  </id_info>
  <brief_title>Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF</brief_title>
  <acronym>IVT-RNFL</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is&#xD;
      currently the standard treatment for retinal neovascularization. The VEGF stimulates&#xD;
      endothelial cells' proliferation and migration. It also increases microvascular permeability.&#xD;
      If the VEGFs have proven their efficiency in the decrease of choroidal neovascular&#xD;
      proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown.&#xD;
      Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in&#xD;
      the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have&#xD;
      an incidence on the loss of retinal nerve fibers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in RNFL's thickness in the nasal quadrant of the optic nerve after intra-vitreous Injection of Anti-VEGF</measure>
    <time_frame>Change from baseline RNFL's thickness at Month 12</time_frame>
    <description>RNFL's thickness (in microns) measured with the Heildelberg glaucoma module of the spectral domain Optical Cohérence Tomographie (OCT Spectralis, Heidelberg engeening).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">74</enrollment>
  <condition>Retinal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Patients treated with anti-VEGF</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gonioscopy</intervention_name>
    <description>Study of the trabecular structure by gonioscopy</description>
    <arm_group_label>Patients treated with anti-VEGF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited during a consultation in ophtalmology after prescription of an&#xD;
        anti-VEGF treatment.&#xD;
&#xD;
        The study will not change the patient's usual care schedule. Only a different analysis of&#xD;
        the images obtained by SD -OCT will be performed, and a gonioscopy will be carried out&#xD;
        systematically the inclusion of patient and 12 months.&#xD;
&#xD;
        The data for the study will be collected at the inclusion visit and at the final visit of&#xD;
        the study at 12 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Patients treated with anti-VEGF according to the French summary of product&#xD;
             characteristics (SPC)&#xD;
&#xD;
          -  Patients who have been informed of the trial and who are not opposed to participate in&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients presenting a retinal condition, including the optic nerve&#xD;
&#xD;
          -  Patients treated with anti-VEGF in both eyes&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Lack of affiliation to social security or universal health coverage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Pole Vision du val d'Ouest</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rotchschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre médical et chirurgical de la rétine</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal neovascularization</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>Retinal Nerve Fiber Layer (RNFL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

